NCT04115163View on ClinicalTrials.gov

Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

June 24, 2020

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Metastatic Pancreatic AdenocarcinomaStage IV Pancreatic Cancer AJCC v8
Interventions
DRUG

Gemcitabine

Given IV

DRUG

Nab-paclitaxel

Given IV

Trial Locations (1)

43210

RECRUITING

Ohio State University Comprehensive Cancer Center, Columbus

All Listed Sponsors
lead

Anne Noonan

OTHER